Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales (excluding depreciation and amortization) | 100,158 | 74,615 | 193,740 | 147,652 |
| Research and development | 14,747 | 16,535 | 25,347 | 27,099 |
| Selling, general, and administrative | 91,661 | 81,771 | 165,316 | 158,299 |
| Depreciation and amortization | 19,640 | 23,281 | 40,559 | 46,172 |
| Contingent consideration fair value adjustment | (622) | 1,277 | (804) | (10,815) |
| Total Operating Expenses, net | 225,584 | 197,479 | 424,158 | 368,407 |
| Operating income | 40,460 | 13,892 | 79,348 | 40,086 |
| Other (expense) income, net |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's D&A?
- ANI Pharmaceuticals (ANIP) reported D&A of $19.64M in Q2 2026.
- How has ANI Pharmaceuticals's D&A changed year-over-year?
- ANI Pharmaceuticals's D&A decreased by 15.6% year-over-year, from $23.28M to $19.64M.
- What is the long-term trend for ANI Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's D&A has grown at a 17.9% compound annual growth rate (CAGR), from $47.25M to $91.42M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about ANI Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude